UNSPSC 51343812: Dolutegravir/emitricitabine/tenofovir alafenamide

This classification denotes a combination drug for treatment of HIV. The first component, DOLUTEGRAVIR, has US FDA Unique Ingredient Identifier of DKO1W9H7M1. The second component, EMTRICITABINE, has US FDA Unique Ingredient Identifier of G70B4ETF4S. The third component, TENOFOVIR ALAFENAMIDE, has US FDA Unique Ingredient Identifier of EL9943AG5J.

UNSPSC 51343812 Dolutegravir/emitricitabine/tenofovir alafenamide is a Commodity code that nominally describes a fixed-dose antiretroviral combination product, but recent state and local activity shows minimal direct procurement under this code. The recent opportunities block contains solicitations for EMS pharmaceuticals, long-term care facility pharmacy services, naloxone distribution, forensic drug standards, and mental health prescription services—none of which appear to align with HIV treatment procurement or the specific ARV combination named in the code. The one opportunity explicitly tagged to this code (Dane County's RFP 2026RFP061PR for pharmaceutical services to Badger Prairie Health Care Center) encompasses broad-spectrum pharmacy distribution to a county-owned long-term care facility, not a specialized HIV antiretroviral program. No solicitations in the recent block expressly name dolutegravir/emitricitabine/tenofovir alafenamide or other fixed-dose antiretroviral combinations as a line-item procurement.

State and local procurement activity under this code appears dormant or misaligned with the code's nominal scope. Dane County's long-term care pharmacy RFP is the primary signals-bearing opportunity: it seeks comprehensive pharmaceutical services (daily medication deliveries, dispensing, barcode scanning, quality assurance, and web-based prescription communication) for a 2027–2031 term, with the county currently funding pharmaceutical services at $125,000 annually, local-vendor preference of five bonus points for Dane County location plus two points for adjacent counties, and evaluation weighting heavily on organizational qualifications, service delivery, staffing, cost, and technology integration. Beyond that single long-term care facility procurement, the block contains opportunities for EMS pharmaceuticals (Tucson, City of Tucson Fire Department), mental health prescription services (West Texas Centers), naloxone and drug deactivation systems (Seminole County, Florida), forensic drug standards (Pinellas County, Florida), and regional pharmacy benefits network participation (District of Columbia, RFQ DOC847897)—none of which directly target HIV antiretroviral products. No geographic concentration, repeat-buyer pattern, or sustained pipeline emerges from the data to suggest this code is actively generating state and local procurement for the antiretroviral product named.